Amid cautionary tales of other highly valued unpartnered assets, efgartigimod approaches its US date with destiny.
The clinical hold for Biomarin’s phenylketonuria project comes on the heels of an FDA adcom to discuss gene therapy toxicity.
Despite unconvincing results so far with next-gen IL-2 agents, plenty of groups are still crowding into this space.
Covid-19 vaccine developers stand out as global drug stocks tread water in the first quarter.
Rubius shows the first hints of clinical anticancer activity, and is suddenly worth $2.4bn.
Curevac’s market cap has ballooned almost fivefold since floating, sending the mRNA company into the record books.
The company’s deal with Dragonfly shows that disappointments have not eliminated interest in cytokine approaches.
With a $3.2bn valuation ahead of its Nasdaq float – and a market cap that is now 50% higher – Legend Biotech enters the IPO record books.
The collapse of Rubius’s first attempt to demonstrate the worth of its red blood cell platform proves that this company should never have gone public.